Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12237062 | 0.84 | HCRTR2 (0.42) | HCRTR2HCRTR1ACACBSSTR1SSTR4 | |
| SCHEMBL13627671 | 0.84 | HCRTR2 (0.40) | HCRTR2HCRTR1ACACBSSTR1SSTR4 | |
| SCHEMBL10058625 | 0.81 | RAB9A (0.44) | HRH4 | |
| SCHEMBL13627669 | 0.80 | MEN1 (0.42) | HCRTR2HCRTR1 | |
| SCHEMBL13627378 | 0.79 | HCRTR1 (0.43) | HCRTR2HCRTR1 | |
| SCHEMBL12237054 | 0.76 | HCRTR2 (0.39) | HCRTR2HCRTR1 | |
| SCHEMBL12237069 | 0.76 | MEN1 (0.44) | — | |
| SCHEMBL12849164 | 0.74 | SLC6A2 (0.44) | — | |
| SCHEMBL10058618 | 0.74 | HRH3 (0.37) | CYP2A6 | |
| SCHEMBL12849170 | 0.72 | GRIN1 (0.48) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | HCRTR2 4841/4885HCRTR1 4521/4885ACACB 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.